GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (FRA:AM6) » Definitions » Institutional Ownership

Amicus Therapeutics (FRA:AM6) Institutional Ownership : 56.49% (As of Mar. 04, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Amicus Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Amicus Therapeutics's institutional ownership is 56.49%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Amicus Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Amicus Therapeutics's Float Percentage Of Total Shares Outstanding is 96.69%.


Amicus Therapeutics Institutional Ownership Historical Data

The historical data trend for Amicus Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amicus Therapeutics Institutional Ownership Chart

Amicus Therapeutics Historical Data

The historical data trend for Amicus Therapeutics can be seen below:

2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31
Institutional Ownership 64.82 64.93 65.16 63.43 62.59 60.53 59.97 60.33 56.71 56.49

Amicus Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Amicus Therapeutics Business Description

Traded in Other Exchanges
Address
47 Hulfish Street, Princeton, NJ, USA, 08542
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Amicus Therapeutics Headlines

No Headlines